Close this search box.

Clinical Trial: NRG GU007


Status: Temporarily Closed

Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen DeprIvation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*)

GU007 is temporarily closed to accrual to phase I/dose level 3, effective August 1, 2023.

GU007 Phase II is not open to accrual as of January 27, 2022.